# Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

> **NCT05410821** · PHASE1 · COMPLETED · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 12 (actual)

## Conditions studied

- Refractory Thyroid Gland Carcinoma
- Refractory Thyroid Gland Papillary Carcinoma
- Refractory Thyroid Gland Follicular Carcinoma
- Refractory Thyroid Gland Hurthle Cell Carcinoma

## Interventions

- **DRUG:** 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
- **DRUG:** 177Lu-DOTA-EB-FAPI 2 radionuclide therapy
- **DRUG:** 177Lu-DOTA-EB-FAPI 3 radionuclide therapy

## Key facts

- **NCT ID:** NCT05410821
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-15
- **Primary completion:** 2024-06-15
- **Final completion:** 2025-03-27
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05410821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05410821, "Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05410821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*